


Sales trends by antibiotic class (mg/PCU) from 2010 to 2021^{1,2}



¹ Sales data sorted from highest to lowest in 2021.


² No sales of other quinolones reported in 2020 or 2021.

* The class 'Others' includes sales of imidazole derivatives (metronidazole) and other antibacterials (bacitracin, novobiocin and spectinomycin). Of note is that some of the sales could be for non-food-producing animals.

Since 2011:

- ↓ 19.2% overall annual sales (from 192.5 mg/PCU to 155.6 mg/PCU in 2021)
- ↑ 217.5% 3rd- and 4th-generation cephalosporin sales (from 0.14 mg/PCU to 0.45 mg/PCU in 2021)
- ↑ 119.3% fluoroquinolone sales (from 6.7 mg/PCU to 14.8 mg/PCU in 2021)
- ↓ 100% other quinolone sales (from 0.20 mg/PCU to 0 mg/PCU in 2020–2021)
- ↑ 35.7% polymyxin sales (from 8.9 mg/PCU to 12.1 mg/PCU in 2021)
- ↑ The PCU increased by 10.3% between 2011 and 2021


Proportion of sales (mg/PCU) by product form in 2021¹



Sales of oral powders, oral solutions and premixes accounted for 94.3% of the total sales in 2021.

¹ Sales of other forms (including intramammary, intrauterine and oral paste products) are not represented in the figure and account for 0.6% of total sales. There were no sales of bolus products in 2021.

Proportion of sales (mg/PCU) by AMEG categories in 2021¹



The majority of antibiotic VMP sales in 2021 belonged to the AMEG category D (Prudence), accounting for 66.1% of the total sales.

¹ Novobiocin is not included in the AMEG categorisation and accounts for <0.01% of the overall sales.

2021 sales data

In 2021, overall sales decreased by 4.8% in comparison to 2020 (from 163.4 mg/PCU to 155.6 mg/PCU). The three highest selling antibiotic classes were tetracyclines, penicillins and fluoroquinolones, which accounted for 33.3%, 28.4% and 9.5% of total sales, respectively.



Country information

A national action plan to reduce the spread of antimicrobial resistance was developed in 2018. In line with this action plan, amendments to national legislation on VMPs were made in 2021. The most important measures are the following:

- Antimicrobial VMPs can only be prescribed for food-producing animals for a maximum of 7 days if the product is administered by the animals' owner/keeper;
- The efficacy of any antibiotic treatment administered to food-producing animals should be checked by the responsible veterinarian during an on-site clinical examination;
- The prophylactic use of VMPs containing 3rd- and 4th-generation cephalosporins, fluoroquinolones and colistin is prohibited for food-producing animals;
- Antimicrobial VMPs for food-producing animals may only be prescribed by veterinarians officially authorised to do so.